Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MFGR1877S · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MFGR1877S | DRUG | Intravenous escalating dose |
Inclusion Criteria: * Life expectancy \>/= 12 weeks * ECOG performance status of 0 or 1 * Histologic or cytologic documentation of locally advanced, or metastatic solid malignancy that has relapsed after or failed to respond to at least one prior regimen or for which there is no standard therapy * ...
Top 20 of 25 competitors
MFGR1877S is an investigational small molecule being studied for the treatment of solid tumors and multiple myeloma. It has been evaluated in Phase 1 clinical trials for these oncology indications, though it is not yet approved and remains in clinical development.
MFGR1877S is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company has sponsored clinical trials to evaluate the drug's safety and pharmacokinetics in patients with cancer.
MFGR1877S is in Phase 1 clinical development. It has completed Phase 1 trials for both solid tumors and multiple myeloma, but it is not approved and is still considered investigational.
MFGR1877S has been studied in two completed Phase 1 trials: NCT01122875 for relapsed or refractory t(4;14)-positive multiple myeloma and NCT01363024 for advanced solid tumors. Both trials evaluated safety and pharmacokinetics in adult patients.
MFGR1877S is the primary name for this investigational agent. No alternative names have been reported for this drug in the available clinical trial information.